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ScienceDirectGenetics of HbA1c: a case study in clinical translation
Aaron Leong1,2,4 and Eleanor Wheeler3,4Glycated hemoglobin (HbA1c) measures the amount of glucose
in the blood in the previous 2–3 months and is used to test
whether an individual has diabetes (HbA1c  6.5%), or how
well they are managing their diabetes. Genome-wide
association studies have successfully identified multiple
genomic loci influencing HbA1c, through both glycemic
(factors that affect the amount blood glucose levels) and
erythrocytic (factors that affect the red blood cell) pathways.
Inaccuracies in HbA1c, due to non-glycemic variants, could
lead to suboptimal care or adverse health consequences. A
recently published example is the erythrocytic variant
(rs1050828) in G6PD, which leads to the artificial lowering of
HbA1c and missed diagnosis of diabetes using current
thresholds. In this reviewwewill discuss recent insights into the
genetic etiology of HbA1c, and how these can translate to the
clinic.Addresses
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Introduction
Type 2 diabetes mellitus (T2D) is a complex, heritable
disease, characterized by defects in insulin secretion and/
or insulin action leading to increased blood glucose levels.
Diabetes prevalence is rising dramatically in both devel-
oped and developing countries, in 2014 there were
422 million adults with diabetes and this number is
expected to reach 700 million by 2025 [1]. There are
numerous complications associated with diabetes, includ-
ing long-term microvascular and macrovascular complica-
tions (such as nephropathy, retinopathy, neuropathy,
coronary artery disease, and stroke) and it is estimated
that 1.6 million people die as a result of diabetes and itswww.sciencedirect.comcomplications every year [2]. Despite the serious health
complications, only half of prevalent T2D worldwide has
been clinically diagnosed [3].
Glycated hemoglobin (HbA1c) is a convenient measure of
long-term blood glucose concentrations. This test mea-
sures the proportion of glycated hemoglobin, an irrevers-
ible chemical modification of the hemoglobin molecule
by blood glucose, which reflects average ambient glyce-
mia over the previous 2–3 months, the life of a red blood
cell [4]. Following a World Health Organisation (WHO)
consultation which concluded that HbA1c could be used
to diagnose diabetes [5], HbA1c is now an accepted
diagnostic test for T2D and used for monitoring glycemic
control in patients with diabetes [6]. Unlike direct mea-
sures of blood glucose, such as fasting glucose, which were
historically used to diagnose diabetes, HbA1c is a conve-
nient, and stable indicator of glycemic status, and a good
predictor of T2D-related complications even in individ-
uals without diabetes [7].
Heritability studies have shown that HbA1c is, in part,
genetically determined in individuals with T2D, type
1 diabetes, and those without diabetes [8–10]. In this
review, we present recent insights into the genetic etiol-
ogy of HbA1c and important considerations for the use of
HbA1c in clinical practice.
The genetic etiology of HbA1c
The advent of genome-wide association studies (GWAS),
and combining multiple such studies through large inter-
national consortia such as the Meta-Analysis of Glucose
and Insulin related traits Consortium (MAGIC), have
successfully identified 61 loci influencing HbA1c [11–
15,16 [1_TD$DIFF],17]. These studies suggest that some genetic var-
iants influence HbA1c through glycemic pathways,
whereas others influence HbA1c through nonglycemic
pathways (Figure 1). Interestingly, although HbA1c and
fasting glucose are both used to diagnose diabetes, the
genetic correlation of these traits is only moderate
(rg = 0.412) [18,19], implying that the genetic determinants
of HbA1c do not completely overlap those of glycemia.
Most recently, the MAGIC investigators performed the
largest to date GWAS of HbA1c in up to 159 940 individ-
uals without diabetes of European, African, East Asian,
and South Asian ancestry [16]. They identified
60 genetic variants, explaining 4%–14% of the trait vari-
ance, of which 19 were classified as influencing HbA1c
through glycemic pathways, 22 through erythrocytic path-
ways, and 19 remained unclassified (Figure 2).Current Opinion in Genetics & Development 2018, 50:79–85
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Overview of mechanisms through which genetic variants can influence HbA1c.Nonglycemic pathways influencing HbA1c include fac-
tors affecting erythrocyte biology. Hereditary hemolytic
anemia is associated with reduced erythrocyte lifespan
and therefore likely to cause falsely lower HbA1c relative
to average glycemia [20]. On the other hand, iron defi-
ciency is known to raise HbA1c [21]. Further, thalasse-
mias, other hemoglobin variants (e.g. HbS, HbC, HbD,
HbE), and elevated fetal hemoglobin have been reported
to interfere with some HbA1c laboratory assay methods
[22,23]. As HbA1c is a diagnostic test for diabetes, genetic
variation acting through nonglycemic pathways that
falsely lower HbA1c result in missed T2D cases
[23,24]. Conversely, falsely raised HbA1c can result in
overdiagnoses.
The role of unclassified genetic variants is unclear. It is
possible that some of them may still act through glycemic
or erythrocytic pathways, but studies to date may have
been insufficiently powered to demonstrate any modest
associations with glycemic or erythrocytic measures.
Alternatively, they may be acting through mechanisms
that are neither mediated through between-person varia-
tion in erythrocytic lifespan, erythrocytic biology or gly-
cemia. For instance, the FN3K locus has been identified
through GWAS to be associated to HbA1c but neither
glycemic measures nor erythrocytic indices, and has
therefore remained unclassified [16]. The FN3K gene
encodes fructosamine-3-kinase, an enzyme involved in
deglycation of glycated proteins, a nonglycemic none-
rythrocytic mechanism that likely influences HbA1c.
Implications of G6PD deficiency and sickle
cell trait on the use of HbA1c in people from
different genetic backgrounds
Wheeler et al. [16] found that the genetic architecture of
HbA1c in Europeans and Asians comprised multiple
genetic variants with modest effect sizes. By contrast,
the genetic architecture of HbA1c in African Americans
was dominated by a single missense variant on the X-Current Opinion in Genetics & Development 2018, 50:79–85chromosome in the gene G6PD, rs1050828 (G202A,
alleles C/T, p.Val68Met). G6PD codes for the erythrocyte
enzyme glucose-6-phosphate dehydrogenase, and muta-
tions in this gene can lead to G6PD deficiency, and
hemolytic anemia [25,26] including favism [27]. The
geographic distribution of G6PD deficiency is strongly
correlated with the distribution of malaria, and G6PD
allelic-variants have been found in malarial endemic
regions around the world, specifically parts of the Middle
East, Asia, South America, and most of Africa [28]. Thus,
G6PD deficiency has implications on the diagnostic accu-
racy of HbA1c worldwide, including cosmopolitan areas
where minority groups with recent non-European ances-
try are more likely to carry the G6PD variant. The
particular variant identified by Wheeler and colleagues
was monomorphic in European and Asian populations,
but had minor allele (T) frequency 10%–15% in African
American individuals. The minor allele was associated
with lower HbA1c; an absolute decrease of 0.81%-units
(95% CI 0.66–0.96) for men carrying the T allele, and
0.68%-units (95% CI 0.38–0.97) in women with two
copies (Figure 3). Importantly, to achieve certification
for accurate laboratory reporting of HbA1c values, mea-
sured HbA1c ought to be within 6% of the standard
reference laboratory mean values (i.e., 6.5  0.4%-units)
[29]. The effect of the G6PD variant on HbA1c exceeds
these limits.
The findings of the study have direct clinical implica-
tions. If only a single measure of HbA1c were used to
diagnose T2D, then 650 000 African Americans
(430 000 men and 180 000 women) in the US (approxi-
mately 2% of out of an estimated 29.93 million) with T2D
would remain undiagnosed due to the G6PD variant using
the current threshold of 6.5%-units (Figure 4). Given
individuals with G6PD deficiency are often asymptom-
atic and universal screening is not currently recom-
mended worldwide [25,30], the study suggested investi-
gating the benefits of screening for the G6PD genotypewww.sciencedirect.com
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Manhattan plot illustrating the 60 HbA1c-associated signals identified in Wheeler et al. [16], colored by classification as erythrocytic (red),
glycemic (green) or unclassified (blue). *Distinct secondary signal at the locus.
www.sciencedirect.com Current Opinion in Genetics & Development 2018, 50:79–85
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Mean glycated hemoglobin by genotype for chromosome X
rs1050828.when using HbA1c to diagnose diabetes in populations of
African ancestry, or where G6PD deficiency is common.
In those with G6PD deficiency, direct glucose measure-
ments or adjusted diagnostic thresholds should be used to
diagnose T2D, and it will be important to characterize the
effect of other G6PD variants at this locus.
In an accompanying perspective [31], Paterson noted
that G6PD is subject to X-inactivation a process by which
one of the copies of the X chromosome in females is
inactivated. Depending on which X chromosome is inac-
tive in red cell precursors, the artificial lowering of HbA1c
may differ across heterozygous females (leading to a
larger variance in HbA1c levels in heterozygous (CT)
compared to homozygous (CC) females) despite having
the same genotype at this variant [16].
Similarly, another study examined whether sickle cell
trait (SCT), defined as the presence of one abnormal
allele for HbS at rs334, a variant on chromosome 11, was
associated with differences in HbA1c among African
Americans. Investigators found that, for a given fasting
glucose level, HbA1c values were lower in those with
SCT compared to those without (mean HbA1c differ-
ence, 0.29% (95%CI 0.35, 0.23). The prevalence of
prediabetes and diabetes defined by HbA1c (5.7 to
<6.5%-units, and 6.5%-units, respectively) in African
Americans without a prior diagnosis of diabetes was found
to be over 40% lower among those with SCT compared to
those without. Conversely, they found no difference in
the prevalence of prediabetes or diabetes when defined
by fasting glucose or 2-hour glucose values. These find-
ings suggest that HbA1c may systematically underesti-
mate past glycemia in people with SCT, resulting in
underdiagnosis of T2D in African Americans [32].Current Opinion in Genetics & Development 2018, 50:79–85In the era of precision care, it has become increasingly
important to progress beyond race-based medical prac-
tices to genotype-based medical practices [33]. Genetic
investigations across different ancestral groups may allow
us to eventually isolate the clinical implications of ances-
try-specific HbA1c-related genetic variants from the
social determinants of health that correlate with race/
ethnic groupings. For instance, the mean HbA1c among
Blacks is consistently slightly higher than among Whites
[34,35]. Yet, HbA1c has similar predictive ability for
longitudinal prediction of incident T2D in both races
even after adjusting for fasting glucose and other clinical
variables [36].
Nevertheless, these racial differences in mean HbA1c
continue to spark debate over the extent to which these
differences are genetically determined, and whether
these differences can be explained by differences in
glycemia, social factors, or the quality or access to health-
care. Further, it is unclear whether such differences are
meaningful when using HbA1c in clinical practice [37].
Although the American Diabetes Association acknowl-
edges in clinical practice guidelines that race/ethnicity
can be taken into consideration when using HbA1c to
diagnose diabetes [38], an individual’s unique genotype,
in addition to the socially defined concept of race/ethnic-
ity, needs to be considered when usingHbA1c in diabetes
diagnosis and patient care. Applying a different diagnostic
threshold to all individuals who self-identify as African
American as an attempt to address diagnostic inaccuracy
caused by genetics, such as the G6PD deficiency variant
or sickle cell variant which only affect carriers, would be
inappropriate, and could ironically create greater dispar-
ities in care. Similarly, completely avoiding the use of
HbA1c in clinical practice is probably inappropriate as
HbA1c is a convenient and valid test for the majority of
people. Therefore, a detailed examination of genetic
effects on HbA1c and the frequency by which these
genetic variants differ across ancestrally diverse popula-
tions is a critical next step in elucidating the clinical
implications of HbA1c genetics. Whether HbA1c genet-
ics would be able to explain racial difference in mean
HbA1c remains to be answered.
Implications of HbA1c genetics to HbA1c-
glycemia discordance and precision medicine
Apart from its use as a diagnostic test, HbA1c is also used
to assess overall glycemic control, disease progression,
and response to therapy in people with diabetes [39].
Current management of T2D involves regular measure-
ments of HbA1c and subsequent adjustment of treatment
to lower the HbA1c towards a normal or near-normal
level. As treatment decisions are based on HbA1c,
patients with genetically raised HbA1c through nongly-
cemic mechanisms may overuse medical services, be
over-treated, and have increased rates of side-effects;
whereas patients with genetically lowered HbA1cwww.sciencedirect.com
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Figure 4
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Estimated number of African Americans with type 2 diabetes (T2D) in the US whose diagnoses would be missed due to the glycose-6-phosphate
dehydrogenase (G6PD) variant if screened with glycated hemoglobin (HbA1c). Using NHANES, a representative sample of US in 2013–2014,
investigators estimated that 0.65 million African Americans with type 2 diabetes (T2D) in the US would remain undiagnosed if screened with
glycated hemoglobin (HbA1c) 6.5%-units due to the glycose-6-phosphate dehydrogenase (G6PD) variant. The frequency of the HbA1c-lowering
allele, T, was assumed to be 11% and well-distributed in the population. Total number of African Americans in the US in 2013 was 29.93 million;
mean age was 41; 54% were women. Median HbA1c in this population was 5.5%-units and mean HbA1c was 5.7%-units (SD 0.6). Adjusted T2D
diagnosis threshold for men with the T allele is 5.7%-units, 5.8%-units for women with the TT genotype, and 6.2% for women with the TC
genotype.through nonglycemic mechanisms may have delayed
diagnoses, inadequate treatment, persistent hyperglyce-
mia, and increased rates of T2D-related complications. It
remains uncertain whether genetically induced discor-
dance between HbA1c and glycemia leads to suboptimal
care and adverse health consequences in ways that could
be remedied by use of genetic knowledge.
Measures of the discordance between reported HbA1c
levels and the expected HbA1c level estimated by gly-
cemia include the hemoglobin glycation index and the
glycation gap. The hemoglobin glycation index is calcu-
lated from the difference between the measured HbA1c
level and the HbA1c level predicted from its regression
on mean glucose levels. The glycation gap is calculated
from its regression on fructosamine levels, a glycemic
measure unrelated to erythrocytes. It has been shown that
these measures of HbA1c-glycemia discordance arewww.sciencedirect.comassociated with important health outcomes, including
mortality, microvascular disease, macrovascular disease
and treatment-related hypoglycemia [40–42].
It is possible that genetic variants that influence HbA1c
through nonglycemic pathways are determinants of these
measures of HbA1c-glycemia discordance. Supporting
this hypothesis is a previous study that showed that the
glycation gap may be partly genetically determined and
account for one third of the heritability of HbA1c [43].
Similar to how the sickle cell and G6PD deficiency
variants artificially lower HbA1c through shortening of
the erythrocytic lifespan, some common HbA1c-related
genetic variants may contribute to individual differences
in erythrocytic age. A previous study has shown that
between-person variation in mean erythrocytic age
explains nonglycemic variation in HbA1c and accounting
for this variation likely reduces errors in its estimation ofCurrent Opinion in Genetics & Development 2018, 50:79–85
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related variants that may not influence erythrocytic life-
span or glycemia may also contribute to this discordance.
For instance, differences in fructosamine-3-kinase activ-
ity, which could be caused by variation in the FN3K gene,
have been shown to be associated with the glycation gap
in people with diabetes [45].
Determining which alleles at these HbA1c-related var-
iants raise or lower the hemoglobin glycation index or
glycation gap is necessary to accurately recalibrate HbA1c
values for these genetic effects or derive genotype-
specific diagnostic thresholds for HbA1c, and improve
the diagnostic value and ability of HbA1c to evaluate
glycemic control in patients with T2D regardless of their
genetic background. Importantly, while the majority of
these genetic variants are common in the populations
studied, they have modest effects on HbA1c individually.
Only people carrying multiple of these variants would
have clinically significant discordance between HbA1c
and overall glycemia.
Future directions and conclusions
Large-scale genetic discovery efforts on common human
variation with the potential for direct clinical practice or
public health translation are few and far between. Inves-
tigating how the application of HbA1c genetics can
improve the clinical utility of this valuable biomarker
that is central to T2D diagnosis, risk stratification, pre-
diction, and patient care is an important next step. As
illustrated by the discovery of the G6PD variant in African
Americans, genetic analyses of ethnically diverse popula-
tions offer the possibility of uncovering novel genetic
variants that impact the clinical utility of HbA1c in ethnic
minorities. Similarly, studies focusing on low-frequency
and rare variants, using newer genotyping arrays or denser
imputation panels such as the 1000 Genomes Project [46],
the Haplotype Reference Consortium [47], deep-cover-
age whole genome sequence data from The Trans-Omics
for Precision Medicine (TOPMed) Program (https://
www.nhlbiwgs.org/), or the African Genome Resources
(AGR) panel (https://www.apcdr.org/), may identify addi-
tional variants with clinically meaningful effects on
HbA1c. Findings have the potential to challenge the
manner in which HbA1c is currently used as a diagnostic
tool, inform the individualization of HbA1c-defined
thresholds for screening, and HbA1c-defined goals to
guide treatment decisions, while promoting health equity
for people of different genetic backgrounds, and encour-
aging the practice of precision medicine [48], precision
screening and precision public health.
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